Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 9, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on October 1, 2019 ,
View HTML
Toggle Summary Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series
  Enrollment complete in the Phase 3 MOUNTAIN Study evaluating SAGE-217 in the treatment of major depressive disorder (MDD); topline results expected in 4Q 2019     CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on September 3, 2019 ,
View HTML
Toggle Summary Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder
Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently being investigated in the Phase 3 MOUNTAIN trial for the treatment of MDD, with
View HTML
Toggle Summary Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ (brexanolone) injection CIV, the first treatment specifically indicated for postpartum depression, commercially launched in the U.S. in late-June, with first patients treated in July 2019 Commercial execution is progressing as expected and on-track across key focus areas including
View HTML
Toggle Summary Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on August 1, 2019 , the
View HTML
Toggle Summary Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast”
Data from Phase 2 open-label study of SAGE-217 in bipolar depression demonstrate rapid improvement compared to baseline; analysis of datasets from previously completed studies reveal encouraging findings relevant to the development of SAGE-217 in treatment-resistant depression and generalized
View HTML